HOUSTON (Oct. 1, 2023) — Innovation Map recently highlighted the cutting-edge research of Emerson Perin, MD, PhD, who is utilizing...
HOUSTON (Sept. 15, 2023) — In collaboration with a team of international scientists, Xiao Li, PhD, from the Gene Editing...
HOUSTON (Aug. 22, 2023) — The National Heart, Lung, and Blood Institute (NHLBI) recently awarded The Texas Heart Institute® (THI)...
In a study recently published in the Journal of the American College of Cardiology, researchers examined the association between diets...
In a study recently published in the Journal of the American College of Cardiology researchers examined the association between diets...
FMD is a non-inflammatory, non-atherosclerotic disorder. Meaning it is not caused by inflammation or plaque buildup. FMD causes narrowing or blockage of specific arteries in your body and also can lead to bulging of an artery caused by weakening of the artery wall (“aneurysm”) or a tear in the artery (“dissection”).
New Cell Therapy Offers Potential Treatment Option for Patients With Chronic Heart Failure Houston, TX – February 27, 2023 –...
During its annual day-long Research Symposium on October 20, 2022, The Texas Heart Institute community came together in the Denton...
When considering the effects of COVID-19, we’re likely to think of lung-related issues, like shortness of breath, fatigue, and the...
THI Medical Director Emerson C. Perin, MD, PhD, outlines Phase 3 Clinical Trial Results Demonstrate Promising Stem Cell Treatment Options...
Today more than 30 million patients suffer from painful inflammatory conditions. Prescription opioid pain relievers are commonly prescribed for these...
Grant from the NIH NIDDK to Advance Collaboration to Develop Treatments for Inflammatory Disease HOUSTON, TX, November 10, 2020 –...
Visit U.S. News & World Report
